FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205352274> ?p ?o ?g. }

• W4205352274 endingPage "407" @default.
• W4205352274 startingPage "398" @default.
• W4205352274 abstract "Epitope-based vaccine is a promising personalized cancer immunotherapy; however, a simple and effective approach for its bulk manufacturing is challenging. Current vaccination strategies complicate the process by introducing unnecessary components such as additional delivery carriers, and assembly units. Herein, a type of toll-like receptor 7/8 agonist-epitope conjugate (termed as TLR7/8a-epitope) has been developed as a self-assembled and carrier-free nano vaccine platform, which effectively introduces the antigen and adjuvant with maximum precision, resulting in significantly enhanced dendritic cells (DCs) activation through the MyD88-dependent TLR signaling pathway. TLR7/8a-epitope nanovaccine can prolong the local retention and increase drainage efficiency into the lymph node, eliciting a significantly higher level of CD8 T-cell immunity than those of conventional vaccine formulations. The immunization with TLR7/8a-epitope nanovaccine in mice can not only resist the invasion of B16 cancer cells, but also produce significant therapeutic effects against established B16 melanoma tumors. Therefore, the TLR7/8a-epitope nanovaccine, developed by the direct chemical conjugation of antigen peptide with immunoadjuvant, has great advantages of clear and leanest compositions, controllable and definite preparation process, and remarkable therapeutic effects, representing a new appraoch for personalized cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Herein, a kind of toll-like receptor 7/8 agonist-epitope conjugate was developed and spontaneously self-assemble into nanostructure in aqueous solution without the use of any additional constituents, which can be termed as unique carrier-free nanovaccine platform, providing effectually the leanest vaccine components with maximally and precisely loading of antigen and adjuvant. Significantly, the nanovaccine augmented the immunogenicity of antigenic peptide by increasing DCs activation through MyD88-mediated TLR signaling pathways and promoting T-cell priming. Moreover, nanovaccines could prolong the local retention and further increase the efficiency of drainage into dLNs, which was contributing to efficient initiation of epitope-specific memory and effector T-cell immune responses, leading to effective prophylactic and therapeutic antitumor effects." @default.
• W4205352274 created "2022-01-26" @default.
• W4205352274 creator A5005205203 @default.
• W4205352274 creator A5009451090 @default.
• W4205352274 creator A5010607811 @default.
• W4205352274 creator A5010789290 @default.
• W4205352274 creator A5022890333 @default.
• W4205352274 creator A5046822662 @default.
• W4205352274 creator A5060215226 @default.
• W4205352274 creator A5079289072 @default.
• W4205352274 date "2022-03-01" @default.
• W4205352274 modified "2023-10-10" @default.
• W4205352274 title "Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy" @default.
• W4205352274 cites W1519576779 @default.
• W4205352274 cites W1586699825 @default.
• W4205352274 cites W1611944043 @default.
• W4205352274 cites W1970238011 @default.
• W4205352274 cites W1970957701 @default.
• W4205352274 cites W1972776583 @default.
• W4205352274 cites W1983073871 @default.
• W4205352274 cites W1989525088 @default.
• W4205352274 cites W1991701295 @default.
• W4205352274 cites W1992088744 @default.
• W4205352274 cites W1994993231 @default.
• W4205352274 cites W1999033561 @default.
• W4205352274 cites W2002623789 @default.
• W4205352274 cites W2034729103 @default.
• W4205352274 cites W2051411662 @default.
• W4205352274 cites W2054680036 @default.
• W4205352274 cites W2068064088 @default.
• W4205352274 cites W2074150439 @default.
• W4205352274 cites W2096866753 @default.
• W4205352274 cites W2113847305 @default.
• W4205352274 cites W2114245966 @default.
• W4205352274 cites W2127770027 @default.
• W4205352274 cites W2137158234 @default.
• W4205352274 cites W2141674876 @default.
• W4205352274 cites W2144733364 @default.
• W4205352274 cites W2144887013 @default.
• W4205352274 cites W2289160872 @default.
• W4205352274 cites W2412344701 @default.
• W4205352274 cites W2472361557 @default.
• W4205352274 cites W2564809671 @default.
• W4205352274 cites W2569475586 @default.
• W4205352274 cites W2583976272 @default.
• W4205352274 cites W2586734297 @default.
• W4205352274 cites W2774113098 @default.
• W4205352274 cites W2782035371 @default.
• W4205352274 cites W2785091318 @default.
• W4205352274 cites W2790881625 @default.
• W4205352274 cites W2791512052 @default.
• W4205352274 cites W2887528815 @default.
• W4205352274 cites W2904099327 @default.
• W4205352274 cites W2904210127 @default.
• W4205352274 cites W2908207257 @default.
• W4205352274 cites W2927060731 @default.
• W4205352274 cites W2940091041 @default.
• W4205352274 cites W2940553353 @default.
• W4205352274 cites W2954595910 @default.
• W4205352274 cites W2982049472 @default.
• W4205352274 cites W2999404032 @default.
• W4205352274 cites W3003506669 @default.
• W4205352274 cites W3010991709 @default.
• W4205352274 cites W3034750994 @default.
• W4205352274 cites W3157200140 @default.
• W4205352274 cites W3170549795 @default.
• W4205352274 cites W3192209904 @default.
• W4205352274 doi "https://doi.org/10.1016/j.actbio.2022.01.004" @default.
• W4205352274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35007785" @default.
• W4205352274 hasPublicationYear "2022" @default.
• W4205352274 type Work @default.
• W4205352274 citedByCount "15" @default.
• W4205352274 countsByYear W42053522742022 @default.
• W4205352274 countsByYear W42053522742023 @default.
• W4205352274 crossrefType "journal-article" @default.
• W4205352274 hasAuthorship W4205352274A5005205203 @default.
• W4205352274 hasAuthorship W4205352274A5009451090 @default.
• W4205352274 hasAuthorship W4205352274A5010607811 @default.
• W4205352274 hasAuthorship W4205352274A5010789290 @default.
• W4205352274 hasAuthorship W4205352274A5022890333 @default.
• W4205352274 hasAuthorship W4205352274A5046822662 @default.
• W4205352274 hasAuthorship W4205352274A5060215226 @default.
• W4205352274 hasAuthorship W4205352274A5079289072 @default.
• W4205352274 hasConcept C136449434 @default.
• W4205352274 hasConcept C147483822 @default.
• W4205352274 hasConcept C195616568 @default.
• W4205352274 hasConcept C203014093 @default.
• W4205352274 hasConcept C2776709828 @default.
• W4205352274 hasConcept C2777701055 @default.
• W4205352274 hasConcept C2777863537 @default.
• W4205352274 hasConcept C2778378633 @default.
• W4205352274 hasConcept C2779836521 @default.
• W4205352274 hasConcept C2780674031 @default.
• W4205352274 hasConcept C502942594 @default.
• W4205352274 hasConcept C86803240 @default.
• W4205352274 hasConcept C8891405 @default.
• W4205352274 hasConceptScore W4205352274C136449434 @default.
• W4205352274 hasConceptScore W4205352274C147483822 @default.

• next